plate::explorer™ and Opera™ will help researchers further narrow drug targets.
Evotec Technologies, the Genome Research Institute (GRI) at the University of Cincinnati (UC), and Cincinnati Children’s Hospital Medical Center reported the successful installation at the GRI of a plate::explorer™ with Opera™ High-Content Screening extension to provide the scientific community with high-throughput and high-content screening (HTS/HCS) capabilities.

The Opera HCS platform combines the precision of confocal microscopy with the speed of primary screening. The modular plate::explorer system can be employed for µHTS, HCS, and secondary screening, as well as assay development. The system also enables parallel plate processingfor highest throughput and individual plate treatment for unlimited assay flexibility.

“The plate::explorer is the ideal tool for such a purpose because it provides biochemical and cellular assays with the desired throughput plus great flexibility,” says Gunter Bauer, CBO at Evotec Technologies.

Previous articleSchering-Plough Posts Major Increase in Net Income
Next articleGeneBio and Goodlett Laboratory Launch Proteomics Collaboration